Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1Gt(ESKN92)Hgs
|
abnormal adrenal gland morphology |
J:141205
|
|
abnormal adrenal gland zona fasciculata morphology |
J:141205
|
|
abnormal adrenal gland zona glomerulosa morphology |
J:141205
|
|
abnormal circulating corticosterone level |
J:141205
|
|
normal
adipose tissue phenotype |
J:141205
|
|
enlarged adrenal glands |
J:141205
|
|
normal
growth/size/body region phenotype |
J:141205
|
|
normal
homeostasis/metabolism phenotype |
J:141205
|
|
increased circulating aldosterone level |
J:141205
|
|
increased circulating angiotensinogen level |
J:141205
|
|
increased circulating corticosterone level |
J:141205
|
|
increased liver triglyceride level |
J:141205
|
|
increased renin activity |
J:141205
|
|
increased systemic arterial systolic blood pressure |
J:141205
|
|
normal
renal/urinary system phenotype |
J:141205
|
Nr3c1Gt(ESKN92)Hgs/Nr3c1Gt(ESKN92)Hgs
B6.Cg-Nr3c1Gt(ESKN92)Hgs
|
postnatal lethality, complete penetrance |
J:141205
|
Nr3c1tm1.1Jaci/Nr3c1tm1.1Jaci
Tg(Myh6-cre)2182Mds/0
involves: C57BL/6 * FVB/N
|
abnormal atrial thrombosis |
J:201995
|
|
abnormal calcium ion homeostasis |
J:201995
|
|
abnormal heart echocardiography feature |
J:201995
|
|
abnormal lung morphology |
J:201995
|
|
abnormal myocardial fiber physiology |
J:201995
|
|
abnormal thoracic cavity morphology |
J:201995
|
|
cardiac fibrosis |
J:201995
|
|
cardiac hypertrophy |
J:201995
|
|
normal
cardiovascular system phenotype |
J:201995
|
|
congestive heart failure |
J:201995
|
|
decreased cardiac muscle contractility |
J:201995
|
|
dilated heart left ventricle |
J:201995
|
|
enlarged heart |
J:201995
|
|
heart inflammation |
J:201995
|
|
increased heart left ventricle weight |
J:201995
|
|
increased heart weight |
J:201995
|
|
increased myocardial fiber size |
J:201995
|
|
pathological neovascularization |
J:201995
|
|
poor circulation |
J:201995
|
|
premature death |
J:201995
|
|
respiratory distress |
J:201995
|
|
thick ventricular wall |
J:201995
|
Nr3c1tm1.1Jda/Nr3c1+
Tg(Lck-cre)548Jxm/0
B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm
|
decreased thymocyte apoptosis |
J:189951
|
Nr3c1tm1.1Jda/Nr3c1tm1.1Jda
Tg(Lck-cre)548Jxm/0
B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm
|
abnormal humoral immune response |
J:189951
|
|
decreased CD4-positive, alpha-beta T cell number |
J:189951
|
|
decreased CD8-positive, alpha-beta T cell number |
J:189951
|
|
decreased double-positive T cell number |
J:189951
|
|
decreased single-positive T cell number |
J:189951
|
|
decreased thymocyte apoptosis |
J:189951
|
|
thymus hypoplasia |
J:189951
|
Nr3c1tm1.1Mvc/Nr3c1+
Tg(Sim1-cre)1Lowl/0
involves: 129 * C57BL/6 * FVB
|
abnormal hypothalamus physiology |
J:179918
|
|
decreased body weight |
J:179918
|
|
increased circulating adrenocorticotropin level |
J:179918
|
|
increased circulating corticosterone level |
J:179918
|
Nr3c1tm1.1Mvc/Nr3c1tm1.1Mvc
Tg(Sim1-cre)1Lowl/0
involves: 129 * C57BL/6 * FVB
|
lethality, complete penetrance |
J:179918
|
Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL
|
abnormal physiological response to xenobiotic |
J:147914
|
|
decreased adrenal gland zona fasciculata size |
J:147914
|
|
decreased B cell number |
J:147914
|
|
decreased circulating adrenocorticotropin level |
J:147914
|
|
decreased circulating corticosterone level |
J:147914
|
|
decreased circulating testosterone level |
J:147914
|
|
increased mean systemic arterial blood pressure |
J:147914
|
|
small adrenal glands |
J:147914
|
|
thin adrenal cortex |
J:147914
|
Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL
|
abnormal physiological response to xenobiotic |
J:147914
|
|
decreased adrenal gland zona fasciculata size |
J:147914
|
|
decreased B cell number |
J:147914
|
|
decreased CD4-positive, alpha-beta T cell number |
J:147914
|
|
decreased CD8-positive, alpha-beta T cell number |
J:147914
|
|
decreased circulating adrenocorticotropin level |
J:147914
|
|
decreased circulating corticosterone level |
J:147914
|
|
decreased circulating testosterone level |
J:147914
|
|
decreased macrophage cell number |
J:147914
|
|
increased mean systemic arterial blood pressure |
J:147914
|
|
small adrenal glands |
J:147914
|
|
thin adrenal cortex |
J:147914
|
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd
|
abnormal adrenal chromaffin cell morphology |
J:54931
|
|
absent circulating adrenaline |
J:54931
|
|
decreased circulating noradrenaline level |
J:54931
|
|
decreased survivor rate |
J:54931,
J:81588
|
|
neonatal lethality, incomplete penetrance |
J:81588
|
|
perinatal lethality, incomplete penetrance |
J:54931
|
|
respiratory failure |
J:81588
|
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * 129/Sv
|
abnormal alveolocapillary membrane morphology |
J:98065
|
|
abnormal lung development |
J:98065
|
|
abnormal lung morphology |
J:98065
|
|
abnormal pulmonary alveolus epithelial cell morphology |
J:98065
|
|
abnormal pulmonary alveolus morphology |
J:98065
|
|
abnormal surfactant secretion |
J:98065
|
|
decreased type I pneumocyte number |
J:98065
|
|
increased circulating corticosterone level |
J:98065
|
|
increased lung weight |
J:98065
|
|
increased type II pneumocyte number |
J:98065
|
|
perinatal lethality, complete penetrance |
J:98065
|
|
pulmonary hyperplasia |
J:98065
|
|
thick pulmonary interalveolar septum |
J:98065
|
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6
|
abnormal adrenal chromaffin cell morphology |
J:27441
|
|
abnormal adrenal cortex morphology |
J:27441
|
|
abnormal adrenal gland morphology |
J:27441
|
|
abnormal adrenal gland zona reticularis morphology |
J:27441
|
|
abnormal branching involved in terminal bronchiole morphogenesis |
J:27441
|
|
abnormal liver physiology |
J:27441
|
|
abnormal lung development |
J:27441
|
|
abnormal respiratory system development |
J:27441
|
|
absent adrenal medulla |
J:27441
|
|
absent adrenergic chromaffin cells |
J:27441
|
|
atelectasis |
J:27441
|
|
cyanosis |
J:27441
|
|
decreased adrenaline level |
J:27441
|
|
decreased noradrenaline level |
J:27441
|
|
enlarged adrenal glands |
J:27441
|
|
enlarged adrenocortical cell nuclei |
J:27441
|
|
enlarged adrenocortical cells |
J:27441
|
|
impaired lung alveolus development |
J:27441
|
|
increased adrenal gland zona fasciculata size |
J:27441
|
|
increased circulating adrenocorticotropin level |
J:27441
|
|
increased circulating corticosterone level |
J:27441
|
|
neonatal lethality, incomplete penetrance |
J:27441
|
|
respiratory distress |
J:27441
|
Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6
|
abnormal lung development |
J:82174
|
|
abnormal lung morphology |
J:82174
|
|
abnormal thymocyte apoptosis |
J:82174
|
|
neonatal lethality, complete penetrance |
J:81588,
J:82174
|
|
respiratory failure |
J:81588
|
|
thick pulmonary interalveolar septum |
J:82174
|
Nr3c1tm2.1Gsc/Nr3c1+
B6.129P2-Nr3c1tm2.1Gsc
|
abnormal blood-brain barrier function |
J:137157
|
|
decreased T cell apoptosis |
J:126427
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:137157
|
Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd
|
abnormal adrenal chromaffin cell morphology |
J:54931
|
|
absent circulating adrenaline |
J:54931
|
|
decreased circulating noradrenaline level |
J:54931
|
|
decreased erythroid progenitor cell number |
J:58790
|
|
neonatal lethality, complete penetrance |
J:54931
|
Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd * 129X1/SvJ
|
abnormal osteoblast differentiation |
J:160669
|
|
abnormal osteoblast physiology |
J:160669
|
|
normal
skeleton phenotype |
J:160669
|
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
abnormal interleukin-6 secretion |
J:197150
|
|
abnormal monocyte cell number |
J:197150
|
|
abnormal response to CNS ischemic injury |
J:197150
|
|
decreased susceptibility to neuronal excitotoxicity |
J:197150
|
|
increased interleukin-1 beta secretion |
J:197150
|
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Tg(Camk2a-cre)T29-1Stl/0
involves: 129S6/SvEvTac * BALB/c * C57BL
|
abnormal response to CNS ischemic injury |
J:197150
|
|
normal
homeostasis/metabolism phenotype |
J:197150
|
|
normal
nervous system phenotype |
J:197150
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
|
normal
immune system phenotype |
J:137157
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
C.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
|
normal
skeleton phenotype |
J:160669
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Alb1-cre)7Gsc/0
involves: 129P2/OlaHsd * FVB/N
|
decreased body weight |
J:121556
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Camk2a-cre/ERT2)2Gsc/0
involves: 129P2/OlaHsd * FVB/N
|
increased circulating corticosterone level |
J:125230
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Drd1a-cre)AGsc/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
abnormal behavioral response to addictive substance |
J:150544
|
|
abnormal nervous system electrophysiology |
J:150544
|
|
normal
behavior/neurological phenotype |
J:150544
|
|
normal
homeostasis/metabolism phenotype |
J:150544
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Lck-cre)I57Jxm/0
B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm
|
decreased physiological sensitivity to xenobiotic |
J:137157
|
|
decreased T cell apoptosis |
J:137157
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:137157
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal nervous system electrophysiology |
J:150544
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL
|
abnormal adipose tissue distribution |
J:57315
|
|
abnormal fear/anxiety-related behavior |
J:57315
|
|
decreased anxiety-related response |
J:57315
|
|
decreased body length |
J:57315
|
|
decreased body size |
J:57315
|
|
decreased body weight |
J:57315
|
|
decreased bone mineral density |
J:57315
|
|
decreased circulating adrenocorticotropin level |
J:57315
|
|
normal
endocrine/exocrine gland phenotype |
J:57315
|
|
hypersecretion of corticotropin-releasing hormone |
J:57315
|
|
increased adrenocorticotropin level |
J:57315
|
|
increased circulating glucocorticoid level |
J:57315
|
|
osteoporosis |
J:57315
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal bone mineral density |
J:160669
|
|
abnormal bone ossification |
J:160669
|
|
abnormal osteoblast differentiation |
J:160669
|
|
decreased bone mineral density |
J:160669
|
|
decreased bone trabecula number |
J:160669
|
|
increased body length |
J:160669
|
|
increased bone trabecular spacing |
J:160669
|
|
normal
skeleton phenotype |
J:160669
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Slc6a3-icre)1Fto/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
normal
behavior/neurological phenotype |
J:150544
|
|
normal
homeostasis/metabolism phenotype |
J:150544
|
|
normal
nervous system phenotype |
J:150544
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Wap-cre)1Gsc/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal mammary gland alveolus morphology |
J:95548
|
|
abnormal mammary gland growth during pregnancy |
J:95548
|
Nr3c1tm2Ljm/Nr3c1tm2Ljm
Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA
|
absent long-term depression |
J:96260
|
|
behavioral despair |
J:96260
|
|
decreased locomotor activity |
J:96260
|
|
increased circulating corticosterone level |
J:96260
|
Nr3c1tm2Ljm/Nr3c1tm2Ljm
Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal cecum morphology |
J:97484
|
|
abnormal interferon level |
J:97484
|
|
abnormal interleukin level |
J:97484
|
|
abnormal tumor necrosis factor level |
J:97484
|
|
cecum inflammation |
J:97484
|
|
increased susceptibility to endotoxin shock |
J:97484
|
|
increased susceptibility to induced morbidity/mortality |
J:97484
|
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd
|
decreased erythroid progenitor cell number |
J:58790
|
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * C57BL/6
|
increased circulating corticosterone level |
J:67720
|
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * FVB/N
|
abnormal osteoblast physiology |
J:160669
|
|
normal
skeleton phenotype |
J:160669
|
Nr3c1tm3Ljm/Nr3c1tm3Ljm
involves: 129S6/SvEvTac * FVB/N
|
no abnormal phenotype detected |
J:98328
|
Excel File
Analysis Tools